SIG
OREX

Stanford Investment Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Stanford Investment Group’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-21
Closed – – 364
2016
Q4 		$0 Hold
21
– – ﹤0.01% 430
2016
Q3 		$0 Hold
21
– – ﹤0.01% 423
2016
Q2 		$0 Hold
21
– – ﹤0.01% 373
2016
Q1 		$0 Hold
21
– – ﹤0.01% 376
2015
Q4 		$0 Hold
21
– – ﹤0.01% 364
2015
Q3 		$0 Hold
21
– – ﹤0.01% 374
2015
Q2 		$1K Hold
21
– – ﹤0.01% 343
2015
Q1 		$2K Hold
21
– – ﹤0.01% 338
2014
Q4 		$1K Buy
+21
New +$1.05K ﹤0.01% 343

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
GL
GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $944M AUM 90.26% 1-Year Est. Return

Stanford Investment Group's OREX Position: Q1 2017 in Review

Stanford Investment Group sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2017, closing a stake of 21 shares.

Stanford Investment Group first reported a position in OREX in Q4 2014 and held it in 9 quarters. The position peaked at $2K in Q1 2015. 52 funds tracked by Wall St. Rank hold OREX as of Q1 2017.

  • Stanford Investment Group reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Stanford Investment Group sold 21 Orexigen Therapeutics, Inc. shares in Q1 2017.
  • Stanford Investment Group first reported a position in Orexigen Therapeutics, Inc. in Q4 2014 and held it in 9 quarters.
  • Stanford Investment Group's Orexigen Therapeutics, Inc. position peaked at $2K in Q1 2015.
  • 52 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2017.

Based on Stanford Investment Group's 13F filing for Q1 2017.